-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, June 4, Hypertension is the primary risk factor for cardiovascular events, and there are a large number of hypertensive patients in China.
The reporter was informed on the 3rd that the National Medical Products Administration officially approved NuoXinto® (sacubatril and valsartan) for the treatment of essential hypertension.
The reporter was informed on the 3rd that the National Medical Products Administration officially approved NuoXinto® (sacubatril and valsartan) for the treatment of essential hypertension.
Previously, Nuoxinto® (sacubatril and valsartan) was approved to be marketed in China as a treatment drug for heart failure indications.
The approval of the drug this time is expected to promote the management of hypertension treatment from pure blood pressure reduction to full cardiovascular event risk control.
The approval of the drug this time is expected to promote the management of hypertension treatment from pure blood pressure reduction to full cardiovascular event risk control.
It is reported that the results of a phase III clinical study led by Professor Yong Huo from Peking University First Hospital and vice chairman of the Chinese Cardiovascular Health Alliance showed that after 8 weeks of treatment, the antihypertensive effect of sacubitril and valsartan was significantly better than that of valsartan.
Olmesartan (comparative drug), which has the best antihypertensive effect among ARB drugs, can significantly increase the rate of blood pressure compliance in patients.
ARB is currently one of the most commonly used first-line treatments for hypertension .
According to reports, among the many Asian patients with mild to moderate essential hypertension included in the study, Chinese patients accounted for 85%.
Olmesartan (comparative drug), which has the best antihypertensive effect among ARB drugs, can significantly increase the rate of blood pressure compliance in patients.
ARB is currently one of the most commonly used first-line treatments for hypertension .
According to reports, among the many Asian patients with mild to moderate essential hypertension included in the study, Chinese patients accounted for 85%.
A number of studies have also shown that, regardless of the level of blood pressure in hypertensive patients, whether they are associated with risk factors or heart and kidney damage, sacubitril and valsartan show a general antihypertensive effect.
It is reported that the damage to the heart, kidneys, blood vessels and other organs caused by hypertension has significantly increased the risk of cardiovascular death, and the disability mortality rate associated with hypertension remains high.
Professor Yong Huo said: “The management of hypertension in China faces multiple challenges such as low compliance rate, high proportion of comorbidities, and increased target organ damage.
In recent years, hypertension treatment has begun to emphasize blood pressure reduction as the basis, while reducing the risk of cardiovascular events.
Treatment strategies to improve the prognosis of patients.
"
Professor Yong Huo said: “The management of hypertension in China faces multiple challenges such as low compliance rate, high proportion of comorbidities, and increased target organ damage.
In recent years, hypertension treatment has begun to emphasize blood pressure reduction as the basis, while reducing the risk of cardiovascular events.
Treatment strategies to improve the prognosis of patients.
"
Professor Yong Huo believes that sacubitril and valsartan have the characteristics of large drop in blood pressure, fast onset, and 24-hour pressure control.
At the same time , it also shows superior protection to the heart , kidneys, blood vessels and other organs.
Block the chain of cardiovascular events in multiple ways and reduce the risk of cardiovascular events.
He bluntly said that the application of sacubitril and valsartan in the field of hypertension will further optimize the existing treatment plan.
(Finish)
At the same time , it also shows superior protection to the heart , kidneys, blood vessels and other organs.
Block the chain of cardiovascular events in multiple ways and reduce the risk of cardiovascular events.
He bluntly said that the application of sacubitril and valsartan in the field of hypertension will further optimize the existing treatment plan.
(Finish)
Medical Network News, June 4, Hypertension is the primary risk factor for cardiovascular events, and there are a large number of hypertensive patients in China.
The reporter was informed on the 3rd that the National Medical Products Administration officially approved NuoXinto® (sacubatril and valsartan) for the treatment of essential hypertension.
The reporter was informed on the 3rd that the National Medical Products Administration officially approved NuoXinto® (sacubatril and valsartan) for the treatment of essential hypertension.
Previously, Nuoxinto® (sacubatril and valsartan) was approved to be marketed in China as a treatment drug for heart failure indications.
The approval of the drug this time is expected to promote the management of hypertension treatment from pure blood pressure reduction to full cardiovascular event risk control.
The approval of the drug this time is expected to promote the management of hypertension treatment from pure blood pressure reduction to full cardiovascular event risk control.
It is reported that the results of a phase III clinical study led by Professor Yong Huo from Peking University First Hospital and vice chairman of the Chinese Cardiovascular Health Alliance showed that after 8 weeks of treatment, the antihypertensive effect of sacubitril and valsartan was significantly better than that of valsartan.
Olmesartan (comparative drug), which has the best antihypertensive effect among ARB drugs, can significantly increase the rate of blood pressure compliance in patients.
ARB is currently one of the most commonly used first-line treatments for hypertension .
According to reports, among the many Asian patients with mild to moderate essential hypertension included in the study, Chinese patients accounted for 85%.
Olmesartan (comparative drug), which has the best antihypertensive effect among ARB drugs, can significantly increase the rate of blood pressure compliance in patients.
ARB is currently one of the most commonly used first-line treatments for hypertension .
According to reports, among the many Asian patients with mild to moderate essential hypertension included in the study, Chinese patients accounted for 85%.
A number of studies have also shown that, regardless of the level of blood pressure in hypertensive patients, whether they are associated with risk factors or heart and kidney damage, sacubitril and valsartan show a general antihypertensive effect.
It is reported that the damage to the heart, kidneys, blood vessels and other organs caused by hypertension has significantly increased the risk of cardiovascular death, and the disability mortality rate associated with hypertension remains high.
Professor Yong Huo said: “The management of hypertension in China faces multiple challenges such as low compliance rate, high proportion of comorbidities, and increased target organ damage.
In recent years, hypertension treatment has begun to emphasize blood pressure reduction as the basis, while reducing the risk of cardiovascular events.
Treatment strategies to improve the prognosis of patients.
"
Professor Yong Huo said: “The management of hypertension in China faces multiple challenges such as low compliance rate, high proportion of comorbidities, and increased target organ damage.
In recent years, hypertension treatment has begun to emphasize blood pressure reduction as the basis, while reducing the risk of cardiovascular events.
Treatment strategies to improve the prognosis of patients.
"
Professor Yong Huo believes that sacubitril and valsartan have the characteristics of large drop in blood pressure, fast onset, and 24-hour pressure control.
At the same time , it also shows superior protection to the heart , kidneys, blood vessels and other organs.
Block the chain of cardiovascular events in multiple ways and reduce the risk of cardiovascular events.
He bluntly said that the application of sacubitril and valsartan in the field of hypertension will further optimize the existing treatment plan.
(Finish)
At the same time , it also shows superior protection to the heart , kidneys, blood vessels and other organs.
Block the chain of cardiovascular events in multiple ways and reduce the risk of cardiovascular events.
He bluntly said that the application of sacubitril and valsartan in the field of hypertension will further optimize the existing treatment plan.
(Finish)
Medical Network News, June 4, Hypertension is the primary risk factor for cardiovascular events, and there are a large number of hypertensive patients in China.
The reporter was informed on the 3rd that the National Medical Products Administration officially approved NuoXinto® (sacubatril and valsartan) for the treatment of essential hypertension.
The reporter was informed on the 3rd that the National Medical Products Administration officially approved NuoXinto® (sacubatril and valsartan) for the treatment of essential hypertension.
Previously, Nuoxinto® (sacubatril and valsartan) was approved to be marketed in China as a treatment drug for heart failure indications.
The approval of the drug this time is expected to promote the management of hypertension treatment from pure blood pressure reduction to full cardiovascular event risk control.
The approval of the drug this time is expected to promote the management of hypertension treatment from pure blood pressure reduction to full cardiovascular event risk control.
It is reported that the results of a phase III clinical study led by Professor Yong Huo from Peking University First Hospital and vice chairman of the Chinese Cardiovascular Health Alliance showed that after 8 weeks of treatment, the antihypertensive effect of sacubitril and valsartan was significantly better than that of valsartan.
Olmesartan (comparative drug), which has the best antihypertensive effect among ARB drugs, can significantly increase the rate of blood pressure compliance in patients.
ARB is currently one of the most commonly used first-line treatments for hypertension .
According to reports, among the many Asian patients with mild to moderate essential hypertension included in the study, Chinese patients accounted for 85%.
Healthy Healthy Healthy Hospital Hospital Hospital Hypertension Hypertension HypertensionOlmesartan (comparative drug), which has the best antihypertensive effect among ARB drugs, can significantly increase the rate of blood pressure compliance in patients.
ARB is currently one of the most commonly used first-line treatments for hypertension .
According to reports, among the many Asian patients with mild to moderate essential hypertension included in the study, Chinese patients accounted for 85%.
A number of studies have also shown that, regardless of the level of blood pressure in hypertensive patients, whether they are associated with risk factors or heart and kidney damage, sacubitril and valsartan show a general antihypertensive effect.
It is reported that the damage to the heart, kidneys, blood vessels and other organs caused by hypertension has significantly increased the risk of cardiovascular death, and the disability mortality rate associated with hypertension remains high.
Professor Yong Huo said: “The management of hypertension in China faces multiple challenges such as low compliance rate, high proportion of comorbidities, and increased target organ damage.
In recent years, hypertension treatment has begun to emphasize blood pressure reduction as the basis, while reducing the risk of cardiovascular events.
Treatment strategies to improve the prognosis of patients.
"
Professor Yong Huo said: “The management of hypertension in China faces multiple challenges such as low compliance rate, high proportion of comorbidities, and increased target organ damage.
In recent years, hypertension treatment has begun to emphasize blood pressure reduction as the basis, while reducing the risk of cardiovascular events.
Treatment strategies to improve the prognosis of patients.
"
Professor Yong Huo believes that sacubitril and valsartan have the characteristics of large drop in blood pressure, fast onset, and 24-hour pressure control.
At the same time , it also shows superior protection to the heart , kidneys, blood vessels and other organs.
Block the chain of cardiovascular events in multiple ways and reduce the risk of cardiovascular events.
He bluntly said that the application of sacubitril and valsartan in the field of hypertension will further optimize the existing treatment plan.
(Finish)
Heart, heart, heart At the same time , it also shows superior protection to the heart , kidneys, blood vessels and other organs.
Block the chain of cardiovascular events in multiple ways and reduce the risk of cardiovascular events.
He bluntly said that the application of sacubitril and valsartan in the field of hypertension will further optimize the existing treatment plan.
(Finish)
